Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

This study has been completed.
Information provided by:
Mylan Pharmaceuticals Identifier:
First received: March 30, 2008
Last updated: March 31, 2008
Last verified: March 2008
The primary objective of this study was to compare the adhesive quality of the current Mylan estradiol placebo transdermal system, with that of an alternate second generation Mylan estradiol placebo transdermal system following a single system application. As a secondary objective, primary dermal irritation was assessed after removal of each transdermal system.

Condition Intervention Phase
Drug: Estradiol Transdermal System Placebo - Alternate Adhesive
Drug: Estradiol Transdermal System Placebo - Current Adhesive
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Outcomes Assessor)
Official Title: Evaluation of the Adhesion Quality and Primary Dermal Irritation Potential of an Alternate Second Generation Estradiol Transdermal Systems in Normal Healthy Female Volunteers

Resource links provided by NLM:

Further study details as provided by Mylan Pharmaceuticals:

Primary Outcome Measures:
  • Transdermal Adhesion [ Time Frame: within 30 days ]

Enrollment: 39
Study Start Date: January 2003
Study Completion Date: February 2003
Primary Completion Date: February 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Estradiol Transdermal System Placebo - Alternate Adhesive
Drug: Estradiol Transdermal System Placebo - Alternate Adhesive
single application
Placebo Comparator: 2
Estradiol Transdermal System Placebo - Current Adhesive
Drug: Estradiol Transdermal System Placebo - Current Adhesive
single application


Ages Eligible for Study:   40 Years to 66 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age: 40-66 years.
  2. Sex: Females only.
  3. Weight: At least 52 kg (115 lbs) and within 20% of Ideal Body Weight (IBW), as referenced by the Table of ""Desirable Weights of Adults"" from Metropolitan Life Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DERMAL SAFETY STUDY PROTOCOLS).
  4. All subjects should be judged normal and healthy during a prestudy medical evaluation (physical examination, laboratory evaluation and 12-lead ECG) performed within 14 days of the initial patch application.

Exclusion Criteria:

  1. Institutionalized subjects will not be used.
  2. Any prior history of skin diseases (eczema, psoriasis, atopic dermatitis).
  3. Damaged skin in or around test sites that include sunburn, uneven skin tones, tattoos, scars or other disfigurations of the test site.
  4. Abnormal and clinically significant laboratory test results:

    1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DERMAL SAFETY STUDY PROTOCOLS).
    2. Abnormal and clinically relevant ECG tracing.
  5. Subjects who have received an investigational drug within 30 days prior to the initial patch application and/or participated in any transdermal system test for irritation or sensitization within the last 4 weeks.
  6. Allergy or hypersensitivity to any tapes or adhesives (ex. band-aids, medical tape).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00650442

United States, West Virginia
Kendle International Inc.
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
Mylan Pharmaceuticals
Principal Investigator: Thomas S Clark, M.D. Kendle International Inc.
  More Information

Additional Information:
Responsible Party: Will Sullivan, Global Head of Product Risk and Safety Management, Mylan Inc. Identifier: NCT00650442     History of Changes
Other Study ID Numbers: ESTR-02133
Study First Received: March 30, 2008
Last Updated: March 31, 2008

Additional relevant MeSH terms:
Polyestradiol phosphate
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female processed this record on April 26, 2017